FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.
What happened
In August 2025, FDA reviewed Reset IV's website at https://resetiv.com and observed that it offers compounded drug products including semaglutide and tirzepatide. FDA cited website claims that semaglutide is “the same ingredient in Wegovy & Ozempic” and tirzepatide is “the same ingredient in Zepbound & Mounjaro.” FDA said these claims are false or misleading because compounded drugs are not FDA-approved and the claims imply the products are the same as FDA-approved products.
What FDA found
Website claims that compounded semaglutide is “the same ingredient in Wegovy & Ozempic” are false or misleading because compounded drugs are not FDA-approved.
FDCA § 502(a) and § 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Website claims that compounded tirzepatide is “the same ingredient in Zepbound & Mounjaro” are false or misleading because compounded drugs are not FDA-approved.
FDCA § 502(a) and § 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The misbranded products were introduced or delivered for introduction into interstate commerce, a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving, delivering, or offering delivery of misbranded drugs in interstate commerce is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Reset IV to take immediate action, including ceasing and desisting from the misleading language, and to respond in writing within 15 working days describing corrective steps and documentation. If it cannot complete the matter in that time, it must state the reason and a timeline.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and pharmacies that supply or advertise these drugs
- marketing and compliance teams for online drug sellers
This is a summary. Read the original letter on fda.gov.